Product Name: Cagrilintide
CAS: 1415456-99-3
MF:
MW: 0
EINECS: 206-141-6
Background
Amylin is a pancreatic β-cell hormone co-secreted with insulin in response to nutrient intake. Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain. Cagrilintide is the first long-acting amylin analogue being investigated for weight management as a once-weekly treatment in combination with semaglutide. Semaglutide, a GLP-1 receptor agonist, reduces appetite via GLP-1 receptors in the hypothalamus, increases insulin production, and reduces glucagon secretion, delaying gastric emptying. These separate but related mechanisms of action of an amylin-analogue and a GLP-1 receptor agonist appear to have an additive effect on appetite reduction.
Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. This drug is an investigational therapy that reduced body weight in a phase 2 trial when administered as monotherapy in participants without diabetes and with a BMI of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia.
Delivery and Payment
Delivery: We have our own delivery channels, and we are responsible for customs clearance and 100% delivery of the goods to your doorstep.(FedEx/US/UPS/DHL/TNT by air or sea)Payment: T/T, Alibaba trade assurance, Credit cards, Bank transfer, Bitcoin and other payment methods.
Our advantages
